Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Overall, we conclude that PC patients with low expression of VRK2 are sensitive to GSH-targeting therapy, while PC patients with high expression of VRK2 are re-sensitive to GSH-targeting therapy following VRK2 inhibition, indicating genetic aberrance of VRK2 expression stratifies the response of PC to metabolism-targeted therapies
PMC 4423164
FDA AI Guidance 2026: Drug Manufacturing & Digital Health Analyze the FDA CDER 2026 guidance pipeline for artificial intelligence in drug manufacturing and digital health technologies in pharmaceutical development
The prevalence of diabetes could increase to more than 54.9 million between 2015 to 2030, and deaths attributed to it will increase by 38 percent to more than 385,000 people per year
US$ 29.25
US$ 23.40
US$ 20.68
US$ 23.32
